Mylan Prepares To Launch Insulin Glargine After Another Lantus IP Win
IPR Victory In US Follows Favorable District Court Ruling In March
Mylan says it is now ready to launch its Semglee insulin glargine rival to Sanofi’s Lantus in the US upon FDA approval, after removing the final intellectual-property barriers by way of a favorable inter partes review decision.
